Atypia of Undetermined Significance and ThyroSeq v3 Positive Call Rates as Quality Control Metrics for Cytology Laboratory Performance - Mejia-Mejia, Odille; Bravo-Gonzalez, Andres; Sanchez-Avila, Monica; Tjendra, Youley; Santoscoy, Rodrigo; Drews-Elger, Katherine; Zuo, Yiqin; Arias-Abad, Camilo; Gomez, Carmen; Garcia-Buitrago, Monica; Nadji, Mehrdad; Jorda, Merce; et al. (medRxiv, 2024)
Background The Bethesda system (TBS) for reporting thyroid cytopathology recommends an “atypia of undetermined significance (AUS)” rate of 10%. Recent data suggest that this category might be overused when the rate of cases with molecular positive results is low. As a quality metric, we calculated the AUS and positive call rates for our cytology lab and each cytopathologist.Methods A retrospective analysis of all thyroid cytology cases in a 4.5-year period was performed. Cases were stratified by TBS category, and molecular testing results were collected for indeterminate categories. The AUS rate was calculated for each cytopathologist (CP) and the laboratory. The molecular positive call rate (PCR) was calculated with and without the addition of currently negative to the positive results obtained from the ThyroSeq report.Results 7,535 cases were classified as non-diagnostic 7.6%, benign 69%, AUS 17.5%, follicular neoplasm / suspicious for follicular neoplasm 1.4%, suspicious for malignancy 0.7 %, and malignant 3.8%. The AUS rate for each cytopathologist ranged from 9.9-36.8%. The overall PCR for the cytology laboratory was 24% (range 13-35.6% per CP). When including cases with currently negative results, the PCR increased to 35.5% for the cytology laboratory (range 13-42.6% per CP). Comparison analysis indicates a combination of overcalling benign cases and, less frequently, under calling of higher TBS category cases.Conclusions The AUS rate in the context of PCR is a useful metric to assess cytology laboratory and cytopathologists’ performance. Continuous feedback on this metric could help improve the overall quality of reporting thyroid cytology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the University of Miami Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript